Triple-negative breast cancer (TNBC) makes up about 15 to 20% of all breast cancers in the US. It is an aggressive subtype, and it does not respond to the hormone therapies that work for other breast cancers. 

This makes well-characterized Fresh Frozen TNBC Tissue Samples essential for studying how the disease develops, why it resists treatment, and which new targets could help patients.

At Bay Biosciences, we understand this need and provide high-quality human biospecimens that support breast cancer research. These include TNBC Tumor Tissue Samples, Triple Negative Breast Cancer Samples, Fresh Frozen Breast Tumor Tissue, and other TNBC Biospecimens.

Fresh Frozen Tumor Tissue Samples from TNBC Patients

Understanding Triple-Negative Breast Cancer

TNBC is a breast cancer that does not express estrogen receptors, progesterone receptors, or high levels of HER2. 

Pathologists use immunohistochemistry to test for these markers. Because the cancer lacks all three, hormone therapy and HER2-targeted drugs do not work against it.

This cancer type is also very diverse. 

Researchers have described several molecular subtypes, and they differ in their genes, their immune activity, and how they respond to treatment. Because of this variety, Human Breast Cancer Tissue Samples with detailed clinical data help researchers link tumor biology to patient outcomes. 

TNBC also differs from other forms of breast cancer, such as ER/HER2 breast cancer, invasive ductal carcinoma, and ductal carcinoma in situ.

Symptoms of Triple-Negative Breast Cancer

The most common sign is a new lump in the breast or underarm. Other changes may include:

  • A lump or mass in your breast area 
  • A change in the size or shape of the breast
  • Skin changes, such as dimpling or redness
  • Swollen lymph nodes under the arm
  • Breast or nipple pain

TNBC tends to grow quickly, so it is often found between routine screenings. 

However, these symptoms can also appear in other breast conditions. Doctors need a tissue biopsy to confirm the diagnosis.

Causes and Risk Factors of Triple-Negative Breast Cancer

In most patients, doctors cannot find a single clear cause. TNBC most likely develops from a mix of inherited, reproductive, and lifestyle factors, along with changes in the tissue around the tumor. 

Having a risk factor does not mean a person will develop the disease, and many patients with TNBC have none of the factors below.

Inherited genetic changes play a major role. A review of germline mutations in TNBC found that harmful BRCA1/2 mutations are about twice as common in unselected TNBC as in breast cancer overall. 

Moreover, TNBC accounts for nearly 60% of breast cancers in premenopausal women who carry BRCA1 mutations, so doctors often recommend testing the BRCA1 and BRCA2 genes in patients with TNBC. 

Other genes, including PALB2 and FANCM, have also been linked to TNBC. Family history of breast or ovarian cancer also raises the risk. 

A meta-analysis of TNBC risk factors confirmed that family history is linked to higher risk. Young age at diagnosis combined with a family history can raise the chance of a BRCA1/2 mutation to up to 40%.

TNBC is more common in younger women, including women before menopause. The same meta-analysis found that later age at first period, later age at first birth, and breastfeeding were protective. 

On the other hand, longer use of oral contraceptives and higher breast density were linked to higher risk.

Moreover, TNBC is more common in black women, and rates of BRCA mutations in TNBC differ by ethnicity. 

Researchers also study other contributors, such as obesity and long-term inflammation, though their roles are still under investigation. 

Diagnosis of Triple-Negative Breast Cancer

Doctors usually begin with a physical exam and imaging.

Ultrasound and mammography help locate the lump, and MRI or CT scans can show whether the cancer has spread. A biopsy then confirms the diagnosis.

The pathologist tests the tissue for three markers. A tumor is called triple-negative when estrogen and progesterone receptors are present in no more than 1% of cells, and HER2 is absent or very low. 

The pathologist also grades the cancer, and doctors use breast cancer stages to describe how far it has spread. 

Treatment of Triple-Negative Breast Cancer

Treatment usually combines surgery, chemotherapy, and sometimes radiation therapy. 

Because hormone and HER2 therapies do not work, chemotherapy is the main systemic treatment. For early, high-risk disease, doctors often add immunotherapy with pembrolizumab to chemotherapy given before surgery.

Newer options target specific weaknesses. PARP inhibitors, such as olaparib and talazoparib, are approved for patients with BRCA mutations. Antibody-drug conjugates, such as sacituzumab govitecan, help in the metastatic setting. 

Overall, the treatment plan depends on the stage, the patient’s genes, and the biology of the tumor.

Applications of Fresh Frozen TNBC Tissue Samples for Research

Fresh Frozen Human Tissue Samples are frozen soon after collection, which preserves DNA, RNA, and proteins which makes them ideal for sequencing, gene expression studies, and proteomics. 

Researchers can also use matched normal adjacent tissue as a control, so they can compare cancerous and healthy tissue from the same patient.

Tumor heterogeneity is one of the biggest challenges in TNBC. Because different molecular subtypes respond differently to treatment, Tumor Heterogeneity Research relies on well-annotated samples from many patients. 

Researchers also use Breast Cancer Biomarker Research to find markers that predict who will respond to therapy.

Tissue studies are even stronger when paired with biofluids. Matched TNBC serum samples, TNBC plasma samples, and TNBC PBMCs let researchers connect what they see in the tumor with what they measure in the blood. 

Together, these resources support Oncology Tissue Samples programs and Oncology Drug Development.

Frequently Asked Questions

What are Fresh Frozen TNBC Tissue Samples used for?

Researchers use them to study tumor biology, classify TNBC subtypes, and identify biomarkers. They also support drug discovery, diagnostics development, and translational research.

Do you provide matched biofluid samples with TNBC tissue?

Yes. We offer matched human serum samples, human plasma samples, and peripheral blood mononuclear cells (PBMCs) from patients with TNBC.

Can researchers compare TNBC samples with healthy controls?

Yes. Researchers can compare disease samples with normal healthy donor samples to find differences in biomarkers and tissue characteristics.

Are Bay Biosciences’ human biospecimens ethically sourced?

Yes. We collect all human samples through appropriate consent and IRB-approved protocols.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide human biospecimens to pharmaceutical companies, biotechnology organizations, academic institutions, and diagnostic developers. Our comprehensive range of samples includes:

If you have any questions, concerns, or special requests, please don’t hesitate to reach out to us! Our team is always happy to help.